Taro Pharmaceutical Industries - TARO - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Taro Pharmaceutical Industries - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
TARO	New York	2834	http://www.taro.com/	63.97 +1.11
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Taro Pharmaceutical Industries Taro to Announce Results for Year Ended March 31, 2013 - May 16th, 2013 2:24 pm Antibodies Show Higher Probability of Success and a Higher Rate of M&A: Learn Which Antibody Companies Show the Better Risk/Reward in this Exclusive Interview with The Wall Street Transcript - May 3rd, 2013 10:07 am My Thoughts On Taro - Apr 13th, 2013 10:45 pm Taro says FDA approves psoriasis treatment spray - Apr 12th, 2013 3:46 pm Taro Pharmaceutical receives FDA approval For Topicort - Apr 12th, 2013 3:17 pm Taro Receives FDA Approval For Topicort® (desoximetasone) Topical Spray, 0.25% - Apr 12th, 2013 3:16 pm Worried About Volatility? Take A Look At These 3 Low Beta Stocks - Apr 10th, 2013 12:26 pm New Product Development and Pipelines in Smaller Medical Devices Companies: Less European Exposure Results in More Limited Exposure to Downside Risk in Those Troubled Countries Across the Atlantic - Mar 18th, 2013 10:04 am Sun Pharma gains on higher prices for drugs - Feb 22nd, 2013 1:13 am Why Taro Pharmaceutical Is Poised to Keep Popping - Feb 16th, 2013 7:59 am 4 Merger and Acquisition Stock Stories To Start the Week - Feb 11th, 2013 6:45 am Taro Calls Off Merger With Sun - Feb 9th, 2013 11:25 am Taro Pharma says sale to Sun Pharma is canceled - Feb 8th, 2013 12:55 pm Medgenics Stumbles and Tranzyme Looks for Options: Healthcare Recap - Feb 8th, 2013 11:10 am TARO Continues to Post Strong Results - Feb 8th, 2013 8:53 am Sun Pharma Ends Effort to Buy Rest of Taro Pharmaceutical - Feb 8th, 2013 7:05 am Sun Pharma and Taro Announce Termination of Proposed Transaction - Feb 8th, 2013 5:30 am Taro Provides Third Quarter and Fiscal Year to Date Results - Feb 4th, 2013 3:27 pm Taro Provides Third Quarter and Fiscal Year to Date Results - Feb 4th, 2013 3:27 pm Taro to Announce Third Quarter Results on February 4, 2013 - Jan 25th, 2013 3:05 pm View All Current Headlines >>